Published in J Immunol on July 01, 1998
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
Increased expression of interleukin 17 in inflammatory bowel disease. Gut (2003) 9.16
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity (2007) 5.73
Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov (2012) 4.70
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev (2010) 4.48
Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol (2003) 4.45
The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol (2007) 3.51
Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med (2000) 3.14
IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J (2001) 2.84
A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity (2009) 2.59
The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther (2004) 2.54
An overview of IL-17 function and signaling. Cytokine (2008) 2.38
Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol (2005) 2.26
Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum (2008) 2.25
Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine (2008) 2.19
IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther (2004) 2.17
IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res (2001) 2.12
Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci U S A (2000) 2.06
IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol (2009) 1.82
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol (2011) 1.67
Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells. Nature (2014) 1.66
Interleukin-17 and its expanding biological functions. Cell Mol Immunol (2010) 1.55
Interleukin-17 augments tumor necrosis factor-alpha-induced granulocyte and granulocyte/macrophage colony-stimulating factor release from human colonic myofibroblasts. J Gastroenterol (2005) 1.54
Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect Immun (2003) 1.45
IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect (2013) 1.37
Antigen-induced IL-17 response in the peripheral blood mononuclear cells (PBMC) of healthy controls. Clin Exp Immunol (2000) 1.35
Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint. PLoS One (2010) 1.31
Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis (2002) 1.31
Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev Immunol (2009) 1.29
Th17 response and inflammatory autoimmune diseases. Int J Inflam (2011) 1.29
Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther (2009) 1.28
Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol (2009) 1.27
The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep (2009) 1.27
Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis (2002) 1.24
Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol (2002) 1.24
A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One (2011) 1.20
Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res (2012) 1.19
The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res (2002) 1.16
Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm (2014) 1.16
Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology (2009) 1.16
Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res Ther (2008) 1.14
Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis (2000) 1.10
Development, regulation and functional capacities of Th17 cells. Semin Immunopathol (2010) 1.10
Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. J Nutr (2008) 1.10
Gene expression induced by interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid arthritis: upregulation of hyaluronan-binding protein TSG-6. Arthritis Res Ther (2003) 1.08
Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clin Exp Immunol (2008) 1.05
Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol Lett (2008) 1.04
IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol (2005) 1.03
Regulation of autoimmune arthritis by the pro-inflammatory cytokine interferon-gamma. Clin Immunol (2008) 1.02
Dendritic cells as targets for therapy in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.02
Cooperation of interleukin-17 and interferon-gamma on chemokine secretion in human fetal intestinal epithelial cells. Clin Exp Immunol (2001) 1.01
FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine/chemokine expression. Arthritis Rheum (2011) 1.00
Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther (2014) 0.97
IL-17 in the rheumatologist's line of sight. Biomed Res Int (2013) 0.95
Suppression of ongoing experimental arthritis by a chinese herbal formula (huo-luo-xiao-ling dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation. Evid Based Complement Alternat Med (2010) 0.95
Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis (2005) 0.95
Pro-inflammatory mediation of myoblast proliferation. PLoS One (2014) 0.94
Lyme arthritis: current concepts and a change in paradigm. Clin Vaccine Immunol (2007) 0.94
Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford) (2009) 0.93
Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases. J Immunol Res (2015) 0.93
Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis. Arthritis Res (2000) 0.93
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther (2013) 0.92
TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection. Immunotherapy (2010) 0.92
IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol (2000) 0.91
Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer (2014) 0.91
Pathologic finding of increased expression of interleukin-17 in the synovial tissue of rheumatoid arthritis patients. Int J Clin Exp Pathol (2013) 0.91
Antiasthmatic Effects of Herbal Complex MA and Its Fermented Product MA128. Evid Based Complement Alternat Med (2011) 0.90
Sleep disorders and increased risk of autoimmune diseases in individuals without sleep apnea. Sleep (2015) 0.89
Aryl hydrocarbon receptor antagonism mitigates cytokine-mediated inflammatory signalling in primary human fibroblast-like synoviocytes. Ann Rheum Dis (2013) 0.89
Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis. Semin Arthritis Rheum (2008) 0.88
Roles of interleukin-17 in an experimental Legionella pneumophila pneumonia model. Infect Immun (2011) 0.88
Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis. J Clin Immunol (2012) 0.88
Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis. Korean J Pediatr (2010) 0.88
Retinal Astrocytes respond to IL-17 differently than Retinal Pigment Epithelial cells. J Leukoc Biol (2009) 0.87
Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis. Endocrinology (2010) 0.86
Ethanol extract of Angelica gigas inhibits croton oil-induced inflammation by suppressing the cyclooxygenase - prostaglandin pathway. J Vet Sci (2010) 0.86
Role of TH-17 cells in rheumatic and other autoimmune diseases. Rheumatology (Sunnyvale) (2011) 0.86
The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part I. Evid Based Complement Alternat Med (2011) 0.85
Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice. Clin Vaccine Immunol (2006) 0.85
The expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1. Arthritis Res Ther (2011) 0.84
Mechanisms of tissue damage in arthritis. Semin Immunopathol (2014) 0.83
The relationship between asymptomatic organ damage, and serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Interleukin-17A (IL-17A) levels in non-diabetic hypertensive patients. BMC Nephrol (2014) 0.81
Development of a T(H)17 immune response during the induction of murine syngeneic graft-versus-host disease. Cytokine (2010) 0.80
Vitamin D improves cognitive function and modulates Th17/T reg cell balance after hepatectomy in mice. Inflammation (2015) 0.80
Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol (2017) 0.80
Synthesis of a novel thiazolidinedione and evaluation of its modulatory effect on IFN- γ , IL-6, IL-17A, and IL-22 production in PBMCs from rheumatoid arthritis patients. Biomed Res Int (2013) 0.79
Characterization of phenotypes of immune cells and cytokines associated with chronic exposure to Premolis semirufa caterpillar bristles extract. PLoS One (2013) 0.79
Inflammation induced loss of skeletal muscle. Bone (2015) 0.79
Microarray profiling of lymphocytes in internal diseases with an altered immune response: potential and methodology. Mediators Inflamm (2005) 0.79
CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response. Clin Exp Immunol (2014) 0.79
Adiponectin exacerbates collagen-induced arthritis via enhancing Th17 response and prompting RANKL expression. Sci Rep (2015) 0.79
IL-17A potentiates TNFα-induced secretion from human endothelial cells and alters barrier functions controlling neutrophils rights of passage. Pflugers Arch (2013) 0.79
Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol (2011) 0.78
IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK/STAT signaling. Sci Rep (2017) 0.78
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia (2015) 0.77
Evaluation of SV40-transformed synovial fibroblasts in the study of rheumatoid arthritis pathogenesis. Rheumatol Int (2011) 0.77
Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis. Korean J Intern Med (2012) 0.77
Evaluation of Local and Systemic Levels of Interleukin-17, Interleukin-23, and Myeloperoxidase in Response to Periodontal Therapy in Patients with Generalized Aggressive Periodontitis. Inflammation (2015) 0.77
The IL-17A G-197A and IL-17F 7488T/C polymorphisms are associated with increased risk of cancer in Asians: a meta-analysis. Drug Des Devel Ther (2015) 0.76
Focal bone involvement in inflammatory arthritis: the role of IL17. Rheumatol Int (2015) 0.76
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum (1999) 6.39
IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol (1999) 3.52
Bacillus Calmette-Guérin induced aseptic arthritis: an experimental model of reactive arthritis. J Rheumatol (1998) 2.59
Production of interleukin 1 by human endothelial cells. J Immunol (1986) 2.27
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res (2001) 2.12
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine (2000) 2.11
Interferon gamma inhibits interleukin 10 production by monocytes. J Exp Med (1993) 1.96
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest (1998) 1.79
IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest (2000) 1.74
Infliximab-induced aseptic meningitis. Lancet (2001) 1.67
Rheumatoid arthritis associated with ulcerative colitis: a case with severe flare of both diseases after delivery. Ann Rheum Dis (2001) 1.65
Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol (1995) 1.63
The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum (2001) 1.59
Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol (2001) 1.56
Lymphocyte chemotactic activity of human interleukin 1. J Immunol (1984) 1.56
Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol (1998) 1.47
Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.44
B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol (1994) 1.41
The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis (2005) 1.38
The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem (1995) 1.35
Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid. Arthritis Rheum (1986) 1.30
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 1.29
Clinical relevance of antikeratin antibodies in rheumatoid arthritis. Clin Rheumatol (1982) 1.25
IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun (2001) 1.25
Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. Scand J Immunol (1993) 1.20
The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. J Clin Invest (1995) 1.14
Pathways to chronic inflammation in rheumatoid synovitis. Fed Proc (1987) 1.14
Immune interferon enhances the production of interleukin 1 by human endothelial cells stimulated with lipopolysaccharide. J Immunol (1986) 1.12
IL-4 inhibits growth factor-stimulated rheumatoid synoviocyte proliferation by blocking the early phases of the cell cycle. J Immunol (1993) 1.12
Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J Infect Dis (1999) 1.12
Physiopathology of haemophilic arthropathy. Haemophilia (2008) 1.11
Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol (2003) 1.10
Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum (1993) 1.09
CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol (1997) 1.08
Change in the Th1/Th2 phenotype of memory T-cell clones from rheumatoid arthritis synovium. Scand J Immunol (1999) 1.06
Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage (2004) 1.06
The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis (2005) 1.03
Different cytokine production profiles of gamma delta T cell clones: relation to inflammatory arthritis. Eur J Immunol (1994) 1.03
Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum (2010) 1.02
Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford) (2000) 1.02
Early occupational therapy programme increases hand grip strength at 3 months: results from a randomised, blind, controlled study in early rheumatoid arthritis. Ann Rheum Dis (2008) 1.01
Expression of a 32-kDa ligand for the CD40 antigen on activated human T lymphocytes. Eur J Immunol (1993) 1.00
IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction. Rheumatology (Oxford) (2000) 0.99
The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium. Clin Exp Immunol (1996) 0.99
Inhibitor of interleukin-2 in rheumatoid synovial fluid. Arthritis Rheum (1987) 0.99
Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis (2008) 0.99
Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions. J Immunol (1995) 0.98
The mannose 6-phosphate/insulin-like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor. J Biol Chem (1998) 0.96
Rheumatoid arthritis and ankylosing spondylitis - pathology of acute inflammation. Clin Exp Rheumatol (2009) 0.96
Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis (2005) 0.95
Lack of evidence for a direct involvement of muscle infection by parvovirus B19 in the pathogenesis of inflammatory myopathies: a follow-up study. Rheumatology (Oxford) (2003) 0.94
T cell receptor expression and activation of synovial lymphocyte subsets in patients with rheumatoid arthritis. Phenotyping of multiple synovial sites. Arthritis Rheum (1990) 0.94
Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes. Eur J Immunol (1994) 0.93
Lack of functional receptors is the only barrier that prevents caprine arthritis-encephalitis virus from infecting human cells. J Virol (2000) 0.93
The interleukin-17 gene of herpesvirus saimiri. J Virol (1998) 0.92
Increases in CD3+CD4-CD8- T lymphocytes in AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. J Infect Dis (1996) 0.92
Increased production of a Th2 cytokine profile by activated whole blood cells from rheumatoid arthritis patients. J Clin Immunol (1998) 0.92
Evaluation of the placental environment with a new in vitro model of histocultures of early and term placentae: determination of cytokine and chemokine expression profiles. Placenta (2005) 0.92
Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis (2008) 0.91
Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum (1998) 0.91
[Relation between antiperinuclear factors, anti-keratin antibodies and the agglutinating and non-agglutinating rheumatoid factor in chronic polyarthritis]. Z Rheumatol (1983) 0.91
Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann Rheum Dis (2004) 0.90
Increase in human endogenous retrovirus HERV-K (HML-2) viral load in active rheumatoid arthritis. Scand J Immunol (2009) 0.90
Functional CD40 antigen on B cells, dendritic cells and fibroblasts. Adv Exp Med Biol (1995) 0.90
A routine assay for the direct analysis of HLA-DR-related shared epitope and B27 alleles in chronic inflammatory arthritis. J Immunol Methods (2001) 0.89
The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J (1994) 0.89
High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study. Scand J Immunol (1997) 0.89
In-vitro endometrial secretion of human interleukin for DA cells/leukaemia inhibitory factor by explant cultures from fertile and infertile women. Hum Reprod (1995) 0.88
Production and characterization of monoclonal antibodies against the leukemia inhibitory factor low affinity receptor, gp190. J Immunol Methods (1997) 0.88
Severe uveitis followed by reactive arthritis after bacillus Calmette-Guérin therapy. J Rheumatol (1999) 0.88
Molecular cloning of human RP105. Eur J Immunol (1997) 0.87
Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) (2005) 0.86
Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.86
Interleukin 4, but not interleukin 10, regulates the production of inflammation mediators by rheumatoid synoviocytes. Cytokine (1995) 0.85
HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol (2001) 0.85
Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc (1998) 0.85
Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab. Ann Rheum Dis (2005) 0.84
Potential contribution of IL-17-producing Th(1)cells to defective repair activity in joint inflammation: partial correction with Th(2)-promoting conditions. Cytokine (2001) 0.84
Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis. J Clin Immunol (1996) 0.83
Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis. Arthritis Rheum (1995) 0.83
Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis (2005) 0.83
Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. J Endocrinol Invest (1997) 0.83
Human interleukin 4. J Lipid Mediat Cell Signal (1994) 0.83
Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol (2001) 0.82
Anti-myelin-associated glycoprotein antibodies and endoneurial cryoglobulin deposits responsible for a severe neuropathy. Acta Neuropathol (2001) 0.82
Interleukin 4 inhibits polyclonal immunoglobulin secretion and cytokine production by peripheral blood mononuclear cells from rheumatoid arthritis patients. J Clin Immunol (1992) 0.82
Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) (2006) 0.81
Changes in the Th1 or Th2 cytokine dominance in the synovium of rheumatoid arthritis (RA): a kinetic study of the Th subsets in one unusual RA patient. Rheumatology (Oxford) (2000) 0.81
Analysis of lymphocyte subsets in the blood of rheumatoid arthritis patients: correlation with disease activity. J Rheumatol (1983) 0.81
Human cytomegalovirus increases constitutive production of interleukin-6 and leukemia inhibitory factor by bone marrow stromal cells. Blood (1996) 0.81
In-vivo administration of progesterone inhibits the secretion of endometrial leukaemia inhibitory factor in vitro. Mol Hum Reprod (1998) 0.81
High levels of leukaemia inhibitory factor in ARDS. Cytokine (1996) 0.81